The drug reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor through the uveoscleral mostly and through the trabecular meshwork. Lowering IOP starts approximately 3-4 hours after administration, the maximum effect is observed after 8-12 hours, the effect persists for at least 24 hours.
It was established that latanoprost has no significant effect on production of aqueous humor and the blood-brain barrier. In the short-term treatment of patients with psevdoafakiey latanoprost does not cause penetration of fluorescein in the posterior segment of the eye. In the application of latanoprost at therapeutic doses has no significant pharmacological effects on the cardiovascular and respiratory systems.
Acid in the aqueous humor is determined during the first 4 hours, and the plasma – only during the first hour after topical application. Metabolism Latnoprost, as a prodrug in the cornea undergoes hydrolysis under the action of esterase with the formation primobolan for women of a biologically active acid. Latanoprost acid entering the systemic circulation, it is metabolized primarily by the liver fatty acid beta-oxidation to form the 1,2 – dinor- and 1,2,3,4 -. Tetranor-metabolites excretion acid latanoprost is rapidly cleared from the plasma half-life (T 1/2 ) which is about 17 minutes. Systemic clearance is approximately 7 mL / min / kg. Once in the liver beta-oxidation metabolites are excreted primarily by the kidneys. After topical kidney derived approximately 88% of the dose.
– Open-angle glaucoma;
– Increased intraocular pressure.
– Hypersensitivity to latanoprost, and other ingredients;
-Children age (under 18 years).
Precautions: Afak, psevdoafakiya to break the back of the lens capsule; Patients with known risk factors for macular edema (latanoprost for the treatment described cases of macular edema and cystoid including); inflammatory, neovascular or congenital glaucoma (due to lack of sufficient experience with the drug).
Pregnancy lactation Application Latanomol drug during pregnancy is possible only under medical supervision and only if the expected benefit to the mother outweighs the potential risk to the fetus.
Latanoprost and its metabolites may be excreted in breast milk. If necessary, the appointment Latanomol during lactation, breast-feeding should be discontinued.
Dosing and dose
Locally, one drop into the affected eye conjunctival sac, once a day, in the evening. To reduce possible systemic absorption is recommended to put pressure on the middle of the inner corner of the eye for one minute (occlusion of the lacrimal points) after instillation of each drop of the drug.
Do not exceed the daily dose of latanoprost, as the more frequent use of the drug reduces the effect of lowering intraocular pressure.
In the case of dose missing Latanomol following application of the drug is carried out in normal mode, primobolan for women ie does not double the dose.
, depending on the frequency of occurrence of the group are the following side effects: very common:> 1/10; common:> 1/100, <1/10; uncommon> 1/1000, <1/100; rare:> 1/10000, <1/1000; very rare: <1/10000, including isolated reports. From a sight organ: very often – increased pigmentation of the iris, eye irritation (burning sensation, feeling of sand in the eyes, itching, stinging and foreign body sensation), lengthening, thickening, increase in the number and increased pigmentation of eyelashes; often – conjunctival hyperemia, transient point erosion of the epithelium (often asymptomatic), blepharitis, eye pain; rare – swelling of the eyelids, keratitis, blurred vision, rare – iritis / uveitis, macular edema, including cystoid), edema and corneal erosions, periorbital edema, changes in the growth of eyelashes (sometimes causing eye irritation), lengthening, thickening, increase in the number and strengthening vellus hair century distichiasis. On the part of the cardiovascular system: often – heartbeat; very rarely– the progression of angina. On the part of the respiratory organs and mediastinum: rarely – bronchial asthma (including acute attacks or worsening of disease in patients with bronchial asthma in history), shortness of breath. For the skin: rare – skin rash. General disorders: very rarely – a non-specific chest pain. From the nervous system: rare – dizziness, headache. On the part of the musculoskeletal system: rarely – pain muscle pain in the joints.
Overdose Symptoms: . Mucous membrane irritation of the eyes, conjunctival hyperemia or episclera case of overdose symptomatic treatment is recommended latanoprost.
Interaction with other drugs
Pharmaceutical incompatible with eye drops containing thiomersal (developing precipitation reaction).
In appointing the eye drops of different drugs combination therapy should be administered at intervals of not less than 5 minutes. Simultaneous burying two prostaglandin analogues can cause a paradoxical increase in intraocular pressure.
Latanomol contains benzalkonium chloride which may be absorbed by contact lenses. Before burying drops contact lenses should be removed; insert the lens only 15 minutes after instillation.
Latanoprost can cause gradual change in iris color by increasing the amount of brown pigment in the iris. This effect is detected predominantly in patients with mixed colored irises, eg blue-brown, gray-brown, green-brown or yellowish-brown, which is explained by an increase in melanin primobolan for women content in the stromal melanocytes of the iris. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris, and the entire iris or parts thereof, may acquire a more intense brown color. Changes in heavy eye pigmentation therapy is stopped.
Patients with a uniformly blue colored iris of the eye, gray, green or brown discoloration of the iris 2 years after the drug is rarely observed. Which developed color change may be irreversible. Prior to treatment, patients should be informed about the possibility of changing the iris. Latanoprost can cause gradual change eyelashes and vellus hair, such as lengthening, thickening, increased pigmentation, increasing the density and changing the direction of eyelash growth. Eyelash changes are reversible and disappear after cessation of treatment.
Patients applying a drop of only one eye, may develop heterochromia.